Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise Alumis (
NASDAQ:ALMS ) said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients wi
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
What to Know About This Fund’s New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors.
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
An Almus (ALMS) Insider Bought 588,000 Shares for $10.0 Million Biotech innovator Alumis, focused on autoimmune therapies, reported a significant insider buy amid a year of robust stock gains.
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
The Great Rotation: Small-Caps Lead 2026 Market Charge as Tech Giants Stumble The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation," investors are pulling capital from the expensive, AI-saturated titans of the Nasdaq and pouring
